Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.65 |
| ▸ | DPP4 | P27487 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.65 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.65 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.65 |
| ▸ | GAPDH | P04406 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | STAT6 | P42226 | 1/20 | 0.65 |
| ▸ | PI4KA | P42356 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.65 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.65 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.65 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.65 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120551 | 0.90 | ADORA3 (0.69) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL120562 | 0.89 | ADORA3 (0.68) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL10689183 | 0.85 | ADORA3 (0.73) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL8109920 | 0.85 | EHMT1 (0.67) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL3447141 | 0.84 | ADORA1 (0.71) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| Water SCHEMBL4262656 | 0.84 | ADORA1 (0.71) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL13268990 | 0.84 | EHMT1 (0.71) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL8608418 | 0.83 | ADORA1 (0.61) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL3446755 | 0.83 | ADORA1 (0.71) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL8606410 | 0.83 | ADORA1 (0.64) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080213900-A1 | Engineered Protein Kinases Which Can Utilize Modified Nucleotide Triphosphate Substrates | SHOKAT KEVAN | 2008-09-04 | — | — | US | disclosed |
| US-20060263800-A1 | Engineered protein kinases which can utilize modified nucleotide triphosphate substrates | PRINCETON UNIVERSITY | 2006-11-23 | — | — | US | disclosed |
| US-7049116-B2 | Engineered protein kinases which can utilize modified nucleotide triphosphate substrates | PRINCETON UNIVERSITY (US) | 2006-05-23 | — | — | US | disclosed |
| US-7026461-B1 | Radiolabeled nucleotide triphosphate compound where at least on phosphorus atom is radioactive that serves as a substrate for a mutant form of a wild-type kinase but not the wild-type form; kits; use of subtrate in assays to determine if test compounds can modulate said mutant enzyme | PRINCETON UNIVERSITY (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1607481-A1 | Engineered protein kinases which can utilize modified nucleotide triphosphate substrates | PRINCETON UNIVERSITY (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1017823-B1 | ENGINEERED PROTEIN KINASES WHICH CAN UTILIZE MODIFIED NUCLEOTIDE TRIPHOSPHATE SUBSTRATES | UNIV PRINCETON (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1140938-B1 | HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF | UNIV PRINCETON (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-1321467-A2 | High affinity inhibitors for target validation and uses thereof | Princeton University (US) | 2003-06-25 | — | — | EP | disclosed |
| US-20030073218-A1 | High affinity inhibitors for target validation and uses thereof | PRINCETON UNIVERSITY | 2003-04-17 | — | — | US | disclosed |
| US-6521417-B1 | Incubating permeabilized cells expressing mutant kinase with radiolabeled analog; cytolysis, separation by sodium dodecyl sulfate polyacrylamide gel electrophoresis | PRINCETON UNIVERSITY | 2003-02-18 | — | — | US | disclosed |
| US-20020146797-A1 | Engineered protein kinases which can utilize modified nucleotide triphosphate substrates | PRINCETON UNIVERSITY. | 2002-10-10 | — | — | US | disclosed |
| US-6390821-B1 | PHOSPHORYLATION | PRINCETON UNIVERSITY | 2002-05-21 | — | — | US | disclosed |
| US-6383790-B1 | PYRAZOLO(3,4-D)PYRIMIDINE BASED COMPOUND; ANTICARCINOGENIC AGENTS; ANTITUMOR AGENTS | PRINCETON UNIVERSITY | 2002-05-07 | — | — | US | disclosed |
| US-20020016976-A1 | Engineered protein kinases which can utilize modified nucleotide triphosphate substrates | PRINCETON UNIVERSITY | 2002-02-07 | — | — | US | disclosed |
| EP-1140938-A2 | HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF | Princeton University (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000042042-A2 | HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF | PRINCETON UNIVERSITY (US) | 2000-07-20 | — | — | WO | disclosed |
| EP-1017823-A2 | ENGINEERED PROTEIN KINASES WHICH CAN UTILIZE MODIFIED NUCLEOTIDE TRIPHOSPHATE SUBSTRATES | PRINCETON UNIVERSITY (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-1998035048-A2 | ENGINEERED PROTEIN KINASES WHICH CAN UTILIZE MODIFIED NUCLEOTIDE TRIPHOSPHATE SUBSTRATES | PRINCETON UNIVERSITY (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073218-A1 | High affinity inhibitors for target validation and uses thereof | SRC, MARCKS, TEC | ADORA1 4810/4885SMN1; SMN2 4306/4885ADORA3 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.